
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid Ltd has demonstrated significant progress in advancing its clinical programs, particularly with D-PLEX100, which has shown positive efficacy-risk characteristics in a Phase 3 study aimed at preventing surgical site infections. The recent reduction in net loss per share, attributed to a substantial increase in share count, indicates improved financial stability as the company prepares for a critical pre-NDA meeting with the FDA planned for December. Furthermore, a strategic collaboration with AdvanzPharma in the EU highlights the company's commitment to leveraging partnerships that can enhance market potential and investor confidence as it approaches potential product approvals.
Bears say
PolyPid Ltd faces significant risks regarding the efficacy of its product candidates, as the potential failure to deliver statistically significant results in clinical studies poses a substantial threat to the company's valuation. Additionally, even with successful clinical outcomes, there are uncertainties surrounding the approval process by regulatory agencies, which could further diminish the perceived value of its products. Compounded by the complexity surrounding patent protections, which may lead to revenue erosion starting in 2036, these factors contribute to a negative outlook on PolyPid's stock.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares